Navigation Links
Access Pharmaceuticals To Host Third Quarter Investor Call on Wednesday, November 28th
Date:11/15/2012

DALLAS and NEW YORK, Nov. 15, 2012 /PRNewswire/ --ACCESS PHARMACEUTICALS, INC.(OTCBB: ACCP), an emerging biopharmaceutical company, will host an investor call to update investors on MuGard commercialization activities, including progress with pharmacy benefit managers, payers and pharmacy formularies, and other new developments within the program.

The investor conference call is scheduled to be held on Wednesday, November 28, 2012 at 11:00 am ET.  Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time. 

A replay of the call will be available starting on November 28, 2012 at 1:00 pm ET, through December 11, 2012 until 11:59 pm ET.  Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and conference ID number 377785.

About Access:
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, and ProLindac™, a second generation DACH platinum drug. The Company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard and Cobalamin, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.

Company and Media Contact:
Christine Berni
Director of Investor Relations
Access Pharmaceuticals, Inc.
(212) 786-6208


'/>"/>
SOURCE Access Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aratana to Participate in Leerink Swanns November Management Access Days
2. Baptist Health Selects MedeAnalytics Patient Access Intelligence and Revenue Cycle Intelligence Solutions
3. Access Pharmaceuticals Announces Private Placement Financing
4. Surgical Equipment Market to 2018 - Increased Access to Ambulatory Surgical Centers to Drive Outpatient Surgery Volumes
5. Varian Medical Systems Publishes 2012 Sustainability Report Outlining Environmental, Charitable, Safety and Health Access Achievements
6. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
7. Philips continues to improve access to treatment for common cause of death in the U.S. with the delivery of its one-millionth AED
8. NxStage Submits Formal Comments to CMS to Improve Patient Access to Life-changing More Frequent Home Hemodialysis Therapy
9. GHX Selects MicroStrategy to Offer Healthcare Suppliers Enhanced Access to Distributed Medical-Surgical Market Data
10. Oncologists restrict pharmaceutical sales rep access at accelerating rates
11. Sequenom Completes International Distribution Agreements To Expand Access To MaterniT21 PLUS Prenatal Testing Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... 2017 Stock-Callers.com today evaluates the following ... ), Novo Nordisk A/S (NYSE: NVO ), Sucampo ... Holdings Inc. (NASDAQ: PTX ). These stocks belong ... th , 2017, finishing near its session lows. As per ... 0.7%, while shares of health care companies in the S&P ...
(Date:1/20/2017)... BUFFALO, N.Y. , Jan. 20, 2017 /PRNewswire/ ... health programs, has announced the launch of an ... to new guidelines on opioids and helps stem ... Opioids are often prescribed to treat chronic non-cancer ... disease) despite serious risks and lack of evidence ...
(Date:1/20/2017)... January 20, 2017 ... an Nothilfe   Die internationale humanitäre Stadt soll ... zu schaffen   Seine Hoheit Scheich ... VAE sowie Herrscher von Dubai , ... der Hilfe (International Humanitarian City IHC) zu verdreifachen, um ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... “Christmas in Suffolk”: a story of ... Seymour, who lives in Lafayette, Indiana where she works in a daycare and looks ... writes. , Published by Christian Faith Publishing, Sara Seymour’s new book is an adventure ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Knowledge is God’s Lighthouse”: a ... “Knowledge is God’s Lighthouse” is the creation of published author, Gene Gaapf, a retired ... collections. , “I have been writing since high school and have many different ...
(Date:1/20/2017)... ... ... “God's Miracle Man: Against All Odds”: an inspiring affirmation of God’s work. “God's ... Tucker, son of Minister Delores Pinnock and a Jamaican native who lives in Kingston ... sitting up in bed, I felt a pounding headache. It was like a drum ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Aerolib Learning Management System: an On-demand E-learning system for Clinical and Regulatory ... Administration that is based on Aerolib`s successful education methodology of Disease Specific ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... 5,000 SF expansion and facility enhancement of their 503A compounding pharmacy located in ... the growing demand of physicians and patients throughout the United States for high-quality ...
Breaking Medicine News(10 mins):